oncology
GU Cancer

Targeted treatments may prolong pancreatic cancer survival by an extra year

Molecularly targeted treatment can prolong pancreatic cancer survival by one year, but only a fraction of eligible people receive it, a new study shows Results from an observational registry-based study 1,082 pancreatic cancer patients showed that actionable genetic alterations were identified in about a quarter (282) of the patients, but only about 4% of all ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic